Mild Cognitive Impairment (MCI) Subjects
Baseline demographics and clinical data for Mild Cognitive Impairment (MCI) subjects from the ADNI database used in this analysis. The subjects are group by their APOE ε4 carrier status. Mini-Mental State Examination (MMSE), and Alzheimer's Disease Assessment Scale 13-Cognitive Subscale (ADAS-Cog) scores are presented as Mean ± SD.
Data Source
The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Data used in the preparation of this presentation were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (https://adni.loni.usc.edu/).
ADNI is funded as a private-public partnership started in 2004, and supported by the National Institute on Aging, the Foundation for the National Institutes of Health, the Alzheimer’s Association, and dozens of companies. The overall goal of ADNI is to validate biomarkers for Alzheimer’s disease (AD) clinical trials. The Principal Investigator of ADNI is Dr. Michael W. Weiner, MD from the University of Southern California (USC) Laboratory of Neuro Imaging (LONI)’s Image and Data Archive (IDA). The data is the result of long term collaborative efforts across North America and is now in its fifth phase of data collection (ADNI4). For up-to-date information on participation and protocol, please visit: https://adni.loni.usc.edu/about/
As outlined in the Table, 222 MCI subjects were included in the analysis, of which 41% were APOE ε4 carriers.
Subjects were, on average, greater than 70 years of age, with a slightly higher proportion of males. All subjects were evaluated for multiple clinical assessments, including the Mini-Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale 13 - Cognitive Subscale (ADAS Cog) rating scales.
For this analysis subjects with an MMSE between 24 and 30 inclusively, a CDR of 0.5, a reported subjective memory concern, an absence of dementia, and an objective memory loss were categorized as having Mild Cognitive Impairment (MCI).